文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

慢加急性肝衰竭改变接受连续血液透析的危重患者利奈唑胺药代动力学:一项观察性研究

Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.
PubMed 文献 · Ann Intensive Care · 2023-09-12
一句话结论ACLF合并CRRT患者利奈唑胺清除率显著降低,标准剂量600mg bid下77%暴露过高,作者认为可考虑减量并需TDM指导。

这项前瞻性队列研究纳入18例接受利奈唑胺600mg bid的危重患者,其中9例合并ACLF,比较合并与不合并肝衰竭(NLF)者的药代动力学。ACLF组利奈唑胺体内清除率平均1.54 L/h,显著低于NLF组的6.26 L/h(P<0.001)。标准剂量下NLF组仅47%达到谷浓度2-7 mg/L目标,42%暴露不足、11%暴露过高;ACLF组仅20%达标,77%暴露过高、3%暴露不足。蒙特卡洛模拟显示NLF组600mg bid、ACLF组150mg bid达标概率最高(53%)。作者认为鉴于变异性大,需TDM调整剂量,TDM结果回报前ACLF患者可考虑减量以防暴露过高。

要点

  • ACLF合并CRRT患者利奈唑胺体内清除率平均1.54 L/h,显著低于无肝衰竭者的6.26 L/h(P<0.001)。
  • 标准剂量600mg bid下,ACLF组仅20%达到谷浓度2-7 mg/L,77%暴露过高、3%暴露不足;NLF组47%达标、42%暴露不足、11%暴露过高。
  • 蒙特卡洛模拟显示达标概率最高为NLF组600mg bid与ACLF组150mg bid,均为53%。
  • 作者认为鉴于总体变异性高,需进行治疗药物监测(TDM)并调整剂量以优化达标。
  • 作者提出TDM结果回报前,ACLF患者可考虑减量以预防暴露过高。

适用人群与场景

  • 接受连续肾脏替代治疗的危重患者,其中9例合并慢加急性肝衰竭(ACLF),9例不合并肝衰竭(NLF)。

诊断标准与关键阈值

  • 利奈唑胺谷浓度目标范围2-7 mg/L。

处置流程与药物剂量

  • 研究方案为利奈唑胺600 mg bid给药。
  • 蒙特卡洛模拟评估150 mg bid、300 mg bid、450 mg bid、600 mg bid和900 mg bid的谷浓度达标情况。
  • 作者认为TDM结果回报前,ACLF患者可考虑减量以预防暴露过高。

研究设计与关键结果

  • 前瞻性队列研究纳入18例患者,ACLF组9例;利奈唑胺体内清除率ACLF组平均(标准差)1.54(0.52)L/h vs NLF组6.26(2.43)L/h,P<0.001。
  • 标准剂量600 mg bid下达到谷浓度2-7 mg/L:NLF组47%(42%暴露不足、11%暴露过高)vs ACLF组20%(77%暴露过高、3%暴露不足)。
  • 蒙特卡洛模拟达标概率最高:NLF组600 mg bid为53%,ACLF组150 mg bid为53%。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为鉴于总体变异性高,需进行治疗药物监测(TDM)并调整剂量以优化目标达标。
  • 作者提出TDM结果回报前,ACLF患者可考虑减量以预防暴露过高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In acute-on-chronic liver failure (ACLF), adequate antibiotic dosing is challenging due to changes of drug distribution and elimination. We studied the pharmacokinetics of linezolid in critically ill patients with ACLF during continuous renal replacement therapy compared to patients without concomitant liver failure (NLF).

METHODS: In this prospective cohort study, patients received linezolid 600 mg bid. Linezolid serum samples were analyzed by high-performance liquid chromatography. Population pharmacokinetic modelling was performed followed by Monte-Carlo simulations of 150 mg bid, 300 mg bid, 450 mg bid, 600 mg bid, and 900 mg bid to assess trough concentration target attainment of 2-7 mg/L.

RESULTS: Eighteen patients were included in this study with nine suffering from ACLF. Linezolid body clearance was lower in the ACLF group with mean (standard deviation) 1.54 (0.52) L/h versus 6.26 (2.43) L/h for NLF, P < 0.001. A trough concentration of 2-7 mg/L was reached with the standard dose of 600 mg bid in the NLF group in 47%, with 42% being underexposed and 11% overexposed versus 20% in the ACLF group with 77% overexposed and 3% underexposed. The highest probability of target exposure was attained with 600 mg bid in the NLF group and 150 mg bid in the ACLF group with 53%.

CONCLUSION: Linezolid body clearance in ACLF was markedly lower than in NLF. Given the overall high variability, therapeutic drug monitoring (TDM) with dose adjustments seems required to optimize target attainment. Until TDM results are available, a dose reduction may be considered in ACLF patients to prevent overexposure.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Tikiso T, Fuhrmann V, König C, et al. Acute-on-chronic liver failure alters linezolid pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study. Ann Intensive Care. 2023. PMID: 37698659. doi:10.1186/s13613-023-01184-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。